stocktitan.net
Phase 2b Results: Duvakitug Shows 48% Remission Rate in UC, Major Gains in Crohn's Disease
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm the findings.
Adult patients with moderate-to-severe UC or CD, clinicians who treat IBD, researchers tracking new IBD drugs, and patients on biologic or advanced therapies
What To Know
What to know Teva and Sanofi reported Phase 2b results for duvakitug (an anti-TL1A monoclonal antibody) presented at ECCO 2025.
In the RELIEVE UCCD study, duvakitug achieved higher clinical remission rates than placebo in ulcerative colitis (36% at 450 mg; 48% at 900 mg vs 20% placebo at week 14) and higher endoscopic response rates in Crohn’s disease (26% at 450 mg; 48% at 900 mg vs 13% placebo at week 14).
Results were reported across both advanced-therapy–experienced and therapy-naïve subgroups, and the companies said the treatment was generally well tolerated with no new safety signals.
Why this matters These Phase 2b findings suggest duvakitug could become a new treatment option for people with moderate-to-severe UC and CD if later trials confirm benefit and safety. The companies indicated these results will support a Phase 3 program expected to start in the second half of 2025.
Limitations and next steps Phase 2b studies are an early step in drug development. Larger Phase 3 trials are needed to confirm benefit, safety, and which patient groups benefit most. The press release-style article summarizes company-presented data; readers should look for peer-reviewed publications or independent conference abstracts for full study details.
This is company-reported Phase 2b data presented at ECCO; Phase 3 trials were announced to start in H2 2025. Full peer-reviewed data or conference abstracts should be consulted for details on endpoints, subgroups, and safety.
